platinum has been researched along with navitoclax in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abadie-Lacourtoisie, S; Blanc-Fournier, C; Brachet, PE; Briand, M; Clarisse, B; Fabbro, M; Floquet, A; Follana, P; Frenel, JS; Gavoille, C; Giffard, F; Gladieff, L; Joly, F; Just, PA; Kalbacher, E; Leary, A; Leconte, A; Lequesne, J; Lesoin, A; Medioni, J; Poulain, L; Weiswald, LB; You, B | 1 |
1 trial(s) available for platinum and navitoclax
Article | Year |
---|---|
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Topics: Aniline Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thrombocytopenia | 2022 |